Our global network

At Boehringer Ingelheim BioXcellence™, we offer a worldwide biopharmaceutical manufacturing network, with tailored end-to-end solutions that help maintain a reliable supply of biological medicines. Your molecule’s success story starts here.

Our biopharmaceutical production network spans across the globe

We operate multi-product facilities on three continents and four sites that are fully licensed for patient supplies in all major markets; Biberach (Germany), Vienna(Austria), Fremont (California, USA), and Shanghai (China).

What our manufacturing network stands for

Flexibility

We adapt to your needs with harmonized processes and scalable technologies across our global sites. This enables seamless product supply and the agility to navigate evolving market demands.

Supply security

Our worldwide network of state-of-the-art facilities provides cross-site synergies and uninterrupted supply. By minimizing risks, your products reach patients without delay.

Reliability

Consistent quality and on-time delivery are at the heart of what we do. With cGMP-certified operations and decades of biopharma expertise, we deliver dependable performance for every project.

Biberach, Germany

• Late-stage clinical supply, launch preparation and commercial supply
• Mammalian technology for different molecule formats: large-scale cell culture manufacturing in 16 x 15,000 L bioreactors and N-1 perfusion
• Aseptic filling in vials for liquids and lyophilizates

[More about Boehringer Ingelheim's Biberach site](/content/sites-around-world/biberach "More about Boehringer Ingelheim's Biberach site"/index.html)

Vienna, Austria

• Late-stage clinical supply, launch preparation and commercial supply
• [Microbial technology for diverse molecule formats](/content/partnering/boehringer-ingelheim-bioxcellence/newsroom/microbial-bioprocessing-expertise-bioxcellence "Explore our microbial expertise"/index.html): 2 x 6,000 L capacity and corresponding flexible downstream suites
• Mammalian technology for various molecule formats and handling of high-titer processes: 9 x 18,000 L capacity and N-1 perfusion

[More about our cell culture facility in Vienna](/content/partnering/boehringer-ingelheim-bioxcellence/newsroom/cell-culture-plant-vienna-bioxcellence "More about our cell culture facility in Vienna"/index.html)

Fremont, USA

• Late-stage clinical supply, launch preparation and commercial supply
• Mammalian technology: 2 x 2,000 L and 3 x 15,000 L capacity and N-1 perfusion
• Multi-product cell culture manufacturing in two separate trains

[More about our Fremont site](/content/partnering/boehringer-ingelheim-bioxcellence/newsroom/fremont-spotlight-bioxcellence "More about our Fremont site"/index.html)

Shanghai, China

• Late-stage clinical supply, launch preparation and commercial supply
• Mammalian technology for various molecule formats: single-use bioreactors – 3 x 2,000 L, N-1 perfusion and scale-out options
• Aseptic filling in vials for liquids

[More about our biopharma site in China](/content/partnering/boehringer-ingelheim-bioxcellence/newsroom/biopharma-site-china-bioxcellence "More about our biopharma site in China"/index.html)

Maximize your product’s potential with cross-site synergies in our large-scale mammalian manufacturing network.

The similar setup of bioreactors and harmonized procedures in our large-scale cell culture facilities results in high flexibility and supply security for our partners. Whether in the U.S., Germany, or Austria, we offer site-neutral product supply. Seamless operations across sites ensure consistent quality and delivery.

Together with our partners, we’re navigating changing product demands, regulatory or geopolitical complexities. Our team of experts is here to make it happen.

Frequently Asked Questions (FAQ) about our global biopharma manufacturing network

Which Boehringer Ingelheim BioXcellence™ sites are approved by FDA and EMA?

Boehringer Ingelheim BioXcellence™ operates multiple cGMP‑certified manufacturing sites that are all licensed by major regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

This enables the stable supply of biopharmaceuticals to key global markets from different regions within our manufacturing network.

Can biopharmaceutical products be transferred between sites?

Yes, the Boehringer Ingelheim BioXcellence™ manufacturing network is designed to support site‑to‑site technology transfer. Harmonized processes, technical setups and structured transfer approaches enable efficient product transfers while maintaining consistent quality and regulatory compliance.

Read more about our technology transfer approach: Technology transfer | BioXcellence | Boehringer Ingelheim.

How does Boehringer Ingelheim BioXcellence™ support supply security across regions?

Boehringer Ingelheim BioXcellence™ supports supply security through a globally integrated manufacturing network with cross‑site synergies, harmonized quality systems and site‑neutral production concepts.

This setup helps minimize supply risks, increase flexibility and enable reliable patient supply across regions.